Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 123

Similar articles for PubMed (Select 24593201)

1.

Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data.

Nakashima Y, Kondo M, Fukuda T, Harada H, Horiuchi T, Ishinishi T, Jojima H, Kuroda K, Miyahara H, Maekawa M, Nishizaka H, Nagamine R, Nakashima H, Otsuka T, Shono E, Suematsu E, Shimauchi T, Tsuru T, Wada K, Yoshizawa S, Yoshizawa S, Iwamoto Y.

Mod Rheumatol. 2014 Mar;24(2):258-64. doi: 10.3109/14397595.2013.854069.

PMID:
24593201
2.

Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data.

Nakashima Y, Kondo M, Fukuda T, Harada H, Horiuchi T, Ishinishi T, Jojima H, Kuroda K, Miyahara H, Maekawa M, Nishizaka H, Nagamine R, Nakashima H, Otsuka T, Shono E, Suematsu E, Shimauchi T, Tsuru T, Wada K, Yoshizawa S, Yoshizawa S, Iwamoto Y.

Mod Rheumatol. 2013 Apr 8. [Epub ahead of print]

PMID:
23563508
3.

Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria.

Iking-Konert C, Aringer M, Wollenhaupt J, Mosch T, Tuerk S, Feist E, Burmester GR.

Ann Rheum Dis. 2011 Nov;70(11):1986-90. doi: 10.1136/ard.2011.152678. Epub 2011 Aug 29.

4.

The DAS28-ESR cutoff value necessary to achieve remission under the new Boolean-based remission criteria in patients receiving tocilizumab.

Hirabayashi Y, Ishii T; Michinoku Tocilizumab Study Group.

Clin Rheumatol. 2013 Jan;32(1):123-7. doi: 10.1007/s10067-012-2103-4. Epub 2012 Oct 23.

5.

Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure.

Genovese MC, Rubbert-Roth A, Smolen JS, Kremer J, Khraishi M, Gómez-Reino J, Sebba A, Pilson R, Williams S, Van Vollenhoven R.

J Rheumatol. 2013 Jun;40(6):768-80. doi: 10.3899/jrheum.120687. Epub 2013 Mar 1.

PMID:
23457383
6.

A review of tocilizumab treatment in 122 rheumatoid arthritis patients included in the Tsurumai Biologics Communication Registry (TBCR) Study.

Yabe Y, Kojima T, Kaneko A, Asai N, Kobayakawa T, Ishiguro N.

Mod Rheumatol. 2013 Mar;23(2):245-53. doi: 10.1007/s10165-012-0648-3. Epub 2012 Apr 22.

PMID:
22526833
7.

Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study.

Lee YC, Cui J, Lu B, Frits ML, Iannaccone CK, Shadick NA, Weinblatt ME, Solomon DH.

Arthritis Res Ther. 2011 Jun 8;13(3):R83. doi: 10.1186/ar3353.

8.

Disability is the major negative predictor for achievement of Boolean-based remission in patients with rheumatoid arthritis treated with tocilizumab.

Hoshi D, Nakajima A, Shidara K, Seto Y, Tanaka E, Taniguchi A, Momohara S, Yamanaka H.

Mod Rheumatol. 2013 Nov;23(6):1205-10. doi: 10.1007/s10165-012-0825-4. Epub 2013 Mar 2.

PMID:
23456321
9.

Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice.

Pers YM, Fortunet C, Constant E, Lambert J, Godfrin-Valnet M, De Jong A, Mercier G, Pallot Prades B, Wendling D, Gaudin P, Jorgensen C, Marotte H, Maillefert JF.

Rheumatology (Oxford). 2014 Jan;53(1):76-84. doi: 10.1093/rheumatology/ket301. Epub 2013 Sep 19.

PMID:
24056521
10.

Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study.

Kojima T, Yabe Y, Kaneko A, Takahashi N, Funahashi K, Kato D, Hanabayashi M, Asai S, Hirabara S, Asai N, Hirano Y, Hayashi M, Miyake H, Kojima M, Ishiguro N.

Rheumatology (Oxford). 2015 Jan;54(1):113-20. doi: 10.1093/rheumatology/keu302. Epub 2014 Aug 7.

PMID:
25102861
11.

High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis.

Daïen CI, Gailhac S, Audo R, Mura T, Hahne M, Combe B, Morel J.

Rheumatology (Oxford). 2015 Apr;54(4):601-8. doi: 10.1093/rheumatology/keu363. Epub 2014 Sep 16.

PMID:
25231180
12.

Active foot synovitis in patients with rheumatoid arthritis: applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement.

Wechalekar MD, Lester S, Proudman SM, Cleland LG, Whittle SL, Rischmueller M, Hill CL.

Arthritis Rheum. 2012 May;64(5):1316-22. doi: 10.1002/art.33506.

13.

Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.

Vermeer M, Kuper HH, Hoekstra M, Haagsma CJ, Posthumus MD, Brus HL, van Riel PL, van de Laar MA.

Arthritis Rheum. 2011 Oct;63(10):2865-72. doi: 10.1002/art.30494.

14.

Shorter disease duration is important for tocilizumab to achieve Boolean remission.

Kawasaki Y, Hashimoto T, Okano T, Sakai Y, Yamane T, Shiozawa K, Shiozawa S, Hashiramoto A.

Mod Rheumatol. 2013 Nov;23(6):1192-7. doi: 10.1007/s10165-012-0822-7. Epub 2013 Feb 5.

PMID:
23380997
15.

Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI.

Suzuki T, Horikoshi M, Sugihara M, Hirota T, Ogishima H, Umeda N, Kondo Y, Tsuboi H, Hayashi T, Chino Y, Matsumoto I, Sumida T.

Mod Rheumatol. 2013 Jul;23(4):782-7. doi: 10.1007/s10165-012-0746-2. Epub 2012 Sep 14.

PMID:
22975733
16.

Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis.

Kojima T, Yabe Y, Kaneko A, Hirano Y, Ishikawa H, Hayashi M, Miyake H, Takagi H, Kato T, Terabe K, Wanatabe T, Tsuchiya H, Kida D, Shioura T, Funahashi K, Kato D, Matsubara H, Takahashi N, Hattori Y, Asai N, Ishiguro N.

Mod Rheumatol. 2013 Sep;23(5):977-85. doi: 10.1007/s10165-012-0782-y. Epub 2012 Oct 26.

PMID:
23099471
17.
18.

Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA).

Burmester GR, Feist E, Kellner H, Braun J, Iking-Konert C, Rubbert-Roth A.

Ann Rheum Dis. 2011 May;70(5):755-9. doi: 10.1136/ard.2010.139725. Epub 2010 Dec 27.

19.

Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index.

Kawashiri SY, Kawakami A, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, Yamasaki S, Nakamura H, Ueki Y, Migita K, Mizokami A, Origuchi T, Aoyagi K, Eguchi K.

Mod Rheumatol. 2011 Aug;21(4):365-9. doi: 10.1007/s10165-010-0402-7. Epub 2011 Jan 13.

PMID:
21229375
20.

Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate.

Nakashima Y, Kondo M, Harada H, Horiuchi T, Ishinishi T, Jojima H, Kuroda K, Miyahara H, Nagamine R, Nakashima H, Otsuka T, Saikawa I, Shono E, Suematsu E, Tsuru T, Wada K, Iwamoto Y.

Mod Rheumatol. 2010 Aug;20(4):343-52. doi: 10.1007/s10165-010-0290-x. Epub 2010 May 18.

PMID:
20480201
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk